Docetaxel rechallenge in metastatic castration-resistant prostate cancer: Any place in the modern treatment scenario? An intention to treat evaluation

Future Oncology

Volumn 11, Issue 22, 2015, Pages 3083-3090

  Bracarda, Sergio ^a   Caserta, Claudia ^b,g   Galli, Luca ^c   Carlini, Paolo ^d   Pastina, Ilaria ^e   Sisani, Michele ^a   Scali, Simona ^f   Hamzaj, Alketa ^a,g   Derosa, Lisa ^c   Felici, Alessandra ^d   Rossi, Marta ^g   Altavilla, Amelia ^a   Chioni, Aldo ^e   De Angelis, Verena ^g  

^a IRCCS POLICLINICO SAN DONATO   (Italy)

^b S MARIA HOSPITAL   (Italy)

^c UNIVERSITY OF PERUGIA   (Italy)

^d UNIVERSITY HOSPITAL OF PISA   (Italy)

^e REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^f MISERICORDIA HOSPITAL   (Italy)

^g ISTITUTO TOSCANO TUMORI   (Italy)

Author keywords

docetaxel; docetaxel rechallenge; intermittent chemotherapy; prostate cancer

Indexed keywords

ABIRATERONE ACETATE; DEXAMETHASONE; DOCETAXEL; ENZALUTAMIDE; PREDNISONE; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CASTRATION RESISTANT PROSTATE CANCER; DRUG EFFICACY; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; MIDDLE AGED; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; VERY ELDERLY; CANCER GRADING; DISEASE COURSE; FOLLOW UP; KAPLAN MEIER METHOD; METASTASIS; MORTALITY; PATHOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RETREATMENT;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; INTENTION TO TREAT ANALYSIS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RETREATMENT; RETROSPECTIVE STUDIES; TAXOIDS; TREATMENT OUTCOME;

EID: 84946887284     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.15.217     Document Type: Article

References (21)

1. Tannock IF, de Wit R, Berry WR et al. TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351(15), 1502-1512 (2004)
2. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351(15), 1513-1520 (2004)
3. Beer TM, Garzotto M, Henner WD et al. Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer. Br. J. Cancer 91(8), 1425-1427 (2004)
4. Tormey DC, Weinberg VE, Leone LA et al. A comparison of intermittent vs. continuous and of adriamycin vs. methotrexate 5-drug chemotherapy for advanced breast cancer. A Cancer and Leukemia Group B study. Am. J. Clin. Oncol. 7(3), 231-239 (1984).
5. Coates A, Gebski V, Bishop JF et al. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N. Engl. J. Med. 317(24), 1490-1495 (1987).
6. Muss HB, Case LD, Richards F 2nd Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. N. Engl. J. Med. 325(19), 1342-1348 (1991).
7. French Epirubicin Study Group. Epirubicinbased chemotherapy in metastatic breast cancer patients: role of dose-intensity and duration of treatment. J. Clin. Oncol. 18(17), 3115-3124 (2000).
8. Maughan TS, James RD, Kerr DJ et al. Medical Research Council Colorectal Cancer Group. Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. Lancet 361(9356), 457-464 (2003).
9. Beer TM, Garzotto M, Henner WD et al. Intermittent chemotherapy in metastatic androgen-independent prostate cancer. Br. J. Cancer 89(6), 968-970 (2003)
10. Beer TM, Ryan CW, Venner PM et al. ASCENT (AIPC Study of Calcitriol ENhancing Taxotere) Investigators. Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a doubleblinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel. Cancer 112(2), 326-330 (2008)
11. Soga N, Kato M, Nishikawa K et al. Intermittent docetaxel therapy with estramustine for hormone-refractory prostate cancer in Japanese patients. Int. J. Clin. Oncol. 14(2), 130-135 (2009).
12. Matsuyama H, Shimabukuro T, Hara I et al. Combination of hemoglobin, alkaline phosphatase, and age predicts optimal docetaxel regimen for patients with castration-resistant prostate cancer. Int. J. Clin. Oncol. 19(5), 946-954 (2014).
13. Halabi S, Small EJ, Kantoff PW et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J. Clin. Oncol. 21, 1232-1237 (2003).
14. Caffo O, Pappagallo G, Brugnara S et al. Multiple rechallenges for castration-resistant prostate cancer patients responding to first-line docetaxel: assessment of clinical outcomes and predictive factors. Urology 79(3), 644-649 (2012).
15. Oudard S, Kramer G, Caffo O et al. Docetaxel rechallenge after an initial good response in patients with metastatic castration-resistant prostate cancer. BJU Int. 15(5), 744-752 (2014).
16. Ansari J, Hussain SA, Zarkar A et al. Docetaxel chemotherapy for metastatic hormone refractory prostate cancer as first-line palliative chemotherapy and subsequent re-treatment: Birmingham experience. Oncol. Rep. 20(4), 891-896 (2008).
17. Bracarda S, Logothetis C, Sternberg CN, Oudard S. Current and emerging treatment modalities for metastatic castration-resistant prostate cancer. BJU Int. 107(2), 13-20 (2011).
18. Bracarda S, Sisani M, Marrocolo F et al. Clinical implications for a treatment algorithm and differential indication to hormone therapy and chemotherapy options in metastatic castrate-resistant prostate cancer: a personal view. Exp. Rev. Anticancer Ther. 14(11), 1283-1294 (2014).
19. Sweeney C, Chen YH, Carducci MA et al. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led Phase III randomized trial. J. Clin. Oncol. 32(Suppl. 5s), Abstract LBA2 (2014).
20. James ND, Spears MR, Clarke NW et al. Survival with newly diagnosed metastatic prostate cancer in the docetaxel era: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019). Eur Urol. 67(6), 1028-1038 (2015).
21. Antonarakis ES, Lu C, Wang H et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl. J. Med. 371(11), 1028-1038 (2014).